CytomX Therapeutics (CTMX) Closes 7.67M Common Stock IPO at $12/Share

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a biopharmaceutical company developing Probody therapeutics for the treatment of cancer, announced the closing of its initial public offering of 7,666,667 shares of common stock at an initial public offering price of $12.00 per share, before underwriting discounts and commissions, which includes the exercise in full by the underwriters of their option to purchase up to 1,000,000 additional shares of common stock. The Company's common stock began trading on The NASDAQ Global Select Market on October 8, 2015, under the ticker symbol "CTMX."

BofA Merrill Lynch, Jefferies LLC and Cowen and Company LLC acted as joint book-running managers for the offering. Oppenheimer & Co. served as manager for the offering.

You May Also Be Interested In

• SpaceX shares gain as lock-up fears ease
• Argus Upgrades SpaceX (SPCX) to Buy
• BlossomHill Therapeutics prices $150M IPO at $16 per share